NEW AGENTS FOR CLL

1. Monoclonal Antobodies -- Luimixilimab -Anti CD23 , Ofatumab - Moab binding to a different epitope other than rituximab
2. Immune modulators -- Lenalidomide
   
3. Cyclin dependent kinase inhibitors -- Flavoperidol ,SNS O32
   
4. BCL-2 Family Member Inhibitors --- Oblimersen ,Obatoclax
5. Protein kinase inhibitor -- Enzastaurine
6. Hsp90 inhibitor ---BII B201
7. SRC kinase inhibitors -- Dasatinib
8. Small modular immune pharmaceutics -TRU -16